VXRT News and Press, Vaxart Inc. From 03/08/23

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednes...

Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in the Phase 2 clinical trial of its oral tablet bivalent ...

The new year is rapidly approaching, which means figuring out how to make money in the stock market. One of the asset classes that has continued outperforming broader markets daily has been stocks under $5. Known as penny stocks , these cheap shares are well-known for their short-term yet...

Summary Today, we revisit Vaxart, Inc. which is developing an oral pill vaccine for Covid as well as other viruses. The company continues to have some challenges and has recently beefed up its management team and disclosed some promising trial results. An investment analysis follows...

Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today that it has appointed Phillip Lee as its Chief Financia...

Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Vaxart, I...

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at...

Shares of micro-cap U.S. vaccine maker Vaxart ( NASDAQ: VXRT ) had fallen 8.6% to $1.27 in late afternoon trading on Wednesday, after its quarterly operating expenses soared and its cash balance narrowed. The company after hours on Tuesday posted Q3 GAAP EPS of -$0.2...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! We’ve got earnings reports, a public o...

Vaxart, Inc. (VXRT) Q3 2022 Earnings Conference Call November 8, 2022, 04:30 PM ET Company Participants Brant Biehn - SVP, Business Operations Cezar Floroiu - CEO, President & Director Sean Tucker - SVP & Chief Scientific Officer James Cummings - Chie...